Logic-gated T cell engager with mutant IL-2 potentiates antitumor responses without cytotoxicity in solid tumor models
Journal of Clinical Investigation · 16.11.2026 · 136 (22)
DOI: 10.1172/jci204657 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 16.11.2026. Verfasst von Shijie Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Changping Laboratory, Beijing, China. Hauptthemen laut MEDLINE: Interleukin-2, Lymphocytes, Tumor-Infiltrating, Mutation, T-Lymphocytes. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, Changping Laboratory.
Abstract (Originalsprache)
T cell engagers (TCEs) have achieved transformative success in B cell malignancies but show limited efficacy in solid tumors with severe toxicity. We propose that TCR signaling without IL-2 might limit the function of tumor-infiltrating lymphocytes (TILs). Here, we showed that insufficient IL-2 signaling is a key bottleneck for sustaining TCE-induced T cell function. Although exogenous IL-2 enhances TCE efficacy, its systemic administration causes more severe toxicity. We engineered a protease-activatable dual-variable domain (DVD) as a pro-antibody to reduce αCD3 off-tumor toxicity. Furthermore, we designed 3 additional mutations for IL-2 (3E) with markedly reduced receptor affinity, which remained inactive in the periphery. By coengineering the DVD and 3E into a single pro-drug molecule (DVD-3E), we achieved conditional IL-2 and TCR cosignaling strictly dependent on cis CD3 engagement within the tumor microenvironment (TME) upon protease cleavage. This logic-gated design restricted both TCE and cytokine activity to the TME, enabling potent antitumor responses without systemic toxicity. Mechanistically, DVD-3E enhanced not only the persistence and effector function of preexisting intratumoral T cells but also expanded TCF1 + TILs, mitigating exhaustion and enabling durable systemic immunity. These findings define a new design principle for logic-gated TCEs that achieve a favorable balance between efficacy and safety, offering a strategy to overcome current therapeutic resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Changping Laboratory, Beijing, China.
- Center for Cancer Biology, School of Basic Medical Sciences, and.
- State Key Laboratory of Molecular Oncology, Tsinghua University, Beijing, China.
- Institute for Molecular and Cellular Therapeutics, Chinese Institutes for Medical Research, Beijing, China.
- School of Basic Medical Sciences, Capital Medical University, Beijing, China.
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Changping Laboratory
Zitieren
APA
Li, S., Li, N., Liu, X., Cai, Y., Wang, M., Wang, H., Fu, Y. X., & Yang, Z. (2026). Logic-gated T cell engager with mutant IL-2 potentiates antitumor responses without cytotoxicity in solid tumor models. Journal of Clinical Investigation, 136(22). https://doi.org/10.1172/jci204657
Vancouver
Li S, Li N, Liu X, Cai Y, Wang M, Wang H, et al. Logic-gated T cell engager with mutant IL-2 potentiates antitumor responses without cytotoxicity in solid tumor models. Journal of Clinical Investigation. 2026;136(22). doi:10.1172/jci204657
BibTeX
@article{Li2026,
author = {Li, Shijie and Li, Nan and Liu, Xiangming and Cai, Yueqi and Wang, Mukai and Wang, Huimin and Fu, Yang-Xin and Yang, Zaopeng},
title = {Logic-gated T cell engager with mutant IL-2 potentiates antitumor responses without cytotoxicity in solid tumor models},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {22},
doi = {10.1172/jci204657}
}
EUVIMED